SEC Form 4 · accession 0001209191-18-005638
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Jan 24, 2018
Accepted (ET)
Jan 26, 2018 · 4:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 24, 2018 | M | 4,310 | $91.05 | A | 46,262 | D | |
| Common Stock | Jan 24, 2018 | M | 4,659 | $86.52 | A | 50,921 | D | |
| Common Stock | Jan 24, 2018 | S | 8,969 | $169.00 | D | 41,952 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | Jan 24, 2018 | M | 4,310 | D | — | Feb 1, 2026 | Common Stock | 4,310 | 19,397 | D |
| Stock Option (Right to Buy)F3 | $86.52 | Jan 24, 2018 | M | 4,659 | D | — | Feb 2, 2027 | Common Stock | 4,659 | 20,193 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 2/2/2016.
- F3The option vests in 16 quarterly installments from 2/3/2017.